All In Biotech

Drug Trial Radar · NCT07723248

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination With Darolutamide Compared With ARPI or Docetaxel in Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate (Himalayas-1)

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Aug 3, 2026

Primary completion

Mar 2028

Study completion Sep 2030

Sponsor

Lead sponsor
ORIC PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Bayer
First posted
Jul 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or enzalutamide) or docetaxel for treating patients with metastatic castration resistant prostate cancer (mCRPC) who were previously treated with abiraterone acetate. The primary objective of this study is to demonstrate superiority in radiographic progression free survival (rPFS) of the investigational arm of rinzimetostat + darolutamide combination versus physician's choice of control: ARPI (darolutamide or enzalutamide) or docetaxel.

Conditions

  • Metastatic Castration Resistant Prostate Cancer

Interventions

  • RinzimetostatDrug

    400 mg once daily (QD)

  • DarolutamideDrug

    600 mg twice daily (BID)

  • EnzalutamideDrug

    160 mg once daily (QD)

  • DocetaxelDrug

    75 mg/m2 intravenously (IV) every 21 days for up to 10 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic Progression Free Survival assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3)Time frame: Randomization up to ~2 years

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Oncura Health

    Glendale, California · Recruiting

  • SSAK Partners, LLC

    Coral Springs, Florida · Recruiting

  • First Urology PSC

    Jeffersonville, Indiana · Recruiting

  • Cancer And Hematology Centers Of Western Michigan

    Holland, Michigan · Recruiting

  • Urology Specialists of the Carolinas - University Place

    Charlotte, North Carolina · Recruiting

  • Gabrail Cancer Center Research

    Canton, Ohio · Recruiting

  • MidLantic Urology LLC

    Bala-Cynwyd, Pennsylvania · Recruiting

  • Keystone Urology Specialists

    Lancaster, Pennsylvania · Recruiting

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina · Recruiting

  • Urology Associates

    Nashville, Tennessee · Recruiting

  • Urology Clinics Of North Texas

    Dallas, Texas · Recruiting

  • Urology Partners of North Texas (UPNT)

    Fort Worth, Texas · Recruiting

  • Houston Metro Urology (HMU)

    Houston, Texas · Recruiting

  • Summit Urology

    Murray, Utah · Recruiting

  • BRCR Global (Network)

    San Juan, Puerto Rico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.